The CAV1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the HeLa human cervical epithelial adenocarcinoma cell line. This model targets the CAV1 gene, encoding caveolin-1, a membrane scaffolding protein essential for caveolae biogenesis and organization of signaling complexes. The polyclonal pool offers a heterogeneous loss-of-function system suitable for studying caveolin-1-dependent cellular processes without clonal isolation artifacts.
HeLa cells were originally isolated from a cervical adenocarcinoma in 1951 and constitute the first immortal human cell line. They are HPV18-positive and exhibit an aneuploid karyotype. HeLa cells are extensively characterized and widely employed in cancer biology, virology, and signal transduction research, providing a robust and reproducible platform for genetic perturbation and pathway analysis.
Caveolin-1 functions primarily as a scaffolding protein within cholesterol-rich caveolae microdomains at the plasma membrane. It physically interacts with numerous signaling molecules, including Src family kinases, H-Ras, eNOS, EGFR, PDGFR, TGF-beta receptors, integrins, and G-proteins. Upstream regulators such as EGF, TGF-beta, Src kinase, integrin ligation, cholesterol, and shear stress modulate caveolin-1 expression and localization. Downstream, caveolin-1 exerts regulatory control over eNOS activity, the Ras-ERK1/2 cascade, PI3K/AKT signaling, STAT3, and Cyclin D1 expression. Its disruption therefore impacts focal adhesion dynamics, EGFR signaling, and eNOS/NO pathways.
In HeLa cells, CRISPR-mediated CAV1 knockout abrogates caveolae ultrastructure, preventing the normal organization of signaling hubs. This loss derepresses Src kinase and ERK1/2 hyperactivation, enhances integrin-mediated adhesion turnover, and increases cell migration and proliferation. The model recapitulates key features of caveolin-1 tumor-suppressive functions lost in numerous cancers, including cervical, breast, and prostate carcinomas, and serves as a versatile tool to dissect caveolin-1??s roles in mechanotransduction and lipid metabolism.
Researchers can employ the CAV1 knockout polyclonal cells in a broad spectrum of experimental paradigms. Representative assays include Western blotting for phosphorylated Src (Y416) and ERK1/2 (T202/Y204), immunofluorescence for actin cytoskeleton remodeling, Transwell migration and invasion assays, transferrin uptake to measure clathrin-independent endocytosis, cholesterol efflux quantification, co-immunoprecipitation of caveolin-1 interactors, and transmission electron microscopy to confirm caveolae absence. The model is well-suited for investigating caveolae-mediated drug delivery, signaling crosstalk, and tumor suppression mechanisms. For additional technical details, please contact Ascent Research.
